JP2006506378A5 - - Google Patents

Download PDF

Info

Publication number
JP2006506378A5
JP2006506378A5 JP2004546158A JP2004546158A JP2006506378A5 JP 2006506378 A5 JP2006506378 A5 JP 2006506378A5 JP 2004546158 A JP2004546158 A JP 2004546158A JP 2004546158 A JP2004546158 A JP 2004546158A JP 2006506378 A5 JP2006506378 A5 JP 2006506378A5
Authority
JP
Japan
Prior art keywords
memantine
donepezil
medicament
use according
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004546158A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006506378A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB2003/004549 external-priority patent/WO2004037234A2/en
Publication of JP2006506378A publication Critical patent/JP2006506378A/ja
Publication of JP2006506378A5 publication Critical patent/JP2006506378A5/ja
Pending legal-status Critical Current

Links

JP2004546158A 2002-10-24 2003-10-23 1−アミノシクロヘキサン誘導体及びアセチルコリンエステラーゼ阻害薬を用いる併用療法 Pending JP2006506378A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42091802P 2002-10-24 2002-10-24
PCT/GB2003/004549 WO2004037234A2 (en) 2002-10-24 2003-10-23 Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011195242A Division JP2011246491A (ja) 2002-10-24 2011-09-07 1−アミノシクロヘキサン誘導体及びアセチルコリンエステラーゼ阻害薬を用いる併用療法

Publications (2)

Publication Number Publication Date
JP2006506378A JP2006506378A (ja) 2006-02-23
JP2006506378A5 true JP2006506378A5 (enExample) 2009-09-10

Family

ID=32176649

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004546158A Pending JP2006506378A (ja) 2002-10-24 2003-10-23 1−アミノシクロヘキサン誘導体及びアセチルコリンエステラーゼ阻害薬を用いる併用療法
JP2011195242A Pending JP2011246491A (ja) 2002-10-24 2011-09-07 1−アミノシクロヘキサン誘導体及びアセチルコリンエステラーゼ阻害薬を用いる併用療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011195242A Pending JP2011246491A (ja) 2002-10-24 2011-09-07 1−アミノシクロヘキサン誘導体及びアセチルコリンエステラーゼ阻害薬を用いる併用療法

Country Status (16)

Country Link
US (6) US20040087658A1 (enExample)
EP (2) EP1556019A2 (enExample)
JP (2) JP2006506378A (enExample)
KR (2) KR100852834B1 (enExample)
CN (1) CN100339070C (enExample)
AU (1) AU2003274353B2 (enExample)
CA (1) CA2502432A1 (enExample)
EA (1) EA008863B1 (enExample)
GE (1) GEP20094759B (enExample)
MX (1) MXPA04006900A (enExample)
NO (1) NO20052462L (enExample)
PL (1) PL376476A1 (enExample)
TW (1) TW200418446A (enExample)
UA (1) UA83645C2 (enExample)
WO (1) WO2004037234A2 (enExample)
ZA (1) ZA200503204B (enExample)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
AU2003298514A1 (en) * 2002-05-17 2004-05-04 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
EP1556019A2 (en) * 2002-10-24 2005-07-27 Merz Pharma GmbH & Co. KGaA Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
CN1870984A (zh) * 2003-10-22 2006-11-29 莫茨药物股份两合公司 1-氨基环己烷衍生物用于调节淀粉样病变中原纤维生成Aβ肽的沉积的用途
CA2551689A1 (en) * 2004-01-05 2005-07-28 Merz Pharma Gmbh & Co. Kgaa Memantine for the treatment of mild and mild-to-moderate alzheimer's disease
TW200531680A (en) * 2004-03-03 2005-10-01 Merz Pharma Gmbh & Co Kgaa Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease
AU2005309601A1 (en) * 2004-11-23 2006-06-01 Neuromolecular Pharmaceuticals, Inc. Composition comprising a sustained release coating or matrix and an NMDA receptor antagonist, method for administration such NMDA antagonist to a subject
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
US8389578B2 (en) 2004-11-24 2013-03-05 Adamas Pharmaceuticals, Inc Composition and method for treating neurological disease
US20060211650A1 (en) * 2004-12-16 2006-09-21 Forest Laboratories, Inc. Reducing carbohydrate derivatives of adamantane amines, and synthesis and methods of use thereof
EP2425846A1 (en) * 2004-12-23 2012-03-07 Voyager Pharmaceutical Corporation Acetylcholinesterase Inhibitors and leuprolide acetate for the treatment of Alzheimer's disease
US20060246003A1 (en) * 2004-12-27 2006-11-02 Eisai Co. Ltd. Composition containing anti-dementia drug
US20060280789A1 (en) * 2004-12-27 2006-12-14 Eisai Research Institute Sustained release formulations
US20090208579A1 (en) * 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
US20060159753A1 (en) * 2004-12-27 2006-07-20 Eisai Co. Ltd. Matrix type sustained-release preparation containing basic drug or salt thereof
US20070129402A1 (en) * 2004-12-27 2007-06-07 Eisai Research Institute Sustained release formulations
US20060160852A1 (en) * 2004-12-27 2006-07-20 Eisai Co. Ltd. Composition containing anti-dementia drug
BRPI0518396A2 (pt) * 2004-12-27 2008-11-18 Eisai R&D Man Co Ltd mÉtodo para estabilizaÇço de droga anti-demÊncia
BRPI0607017B8 (pt) 2005-04-06 2021-05-25 Adamas Pharmaceuticals Inc composição farmacêutica compreendendo memantina e donezepil, e seu uso para o tratamento de condições relacionadas ao snc
CN101166543B (zh) 2005-04-28 2014-07-16 卫材R&D管理有限公司 含抗痴呆药物的组合物
US20070015834A1 (en) * 2005-07-18 2007-01-18 Moshe Flashner-Barak Formulations of fenofibrate containing PEG/Poloxamer
TWI389709B (zh) * 2005-12-01 2013-03-21 Novartis Ag 經皮治療系統
MX2008008213A (es) 2005-12-22 2008-09-03 Neurochem Int Ltd Tratamiento de trastornos renales, nefropatia diabetica y dislipidemias.
EP2420235A1 (en) * 2006-10-27 2012-02-22 Medivation Neurology, Inc. Methods and combination therapies for treating alzheimer's disease
US8278345B2 (en) 2006-11-09 2012-10-02 Probiodrug Ag Inhibitors of glutaminyl cyclase
DK2091948T3 (da) 2006-11-30 2012-07-23 Probiodrug Ag Nye inhibitorer af glutaminylcyclase
EA200901140A1 (ru) 2007-03-01 2010-04-30 Пробиодруг Аг Новое применение ингибиторов глутаминилциклазы
DK2142514T3 (da) 2007-04-18 2015-03-23 Probiodrug Ag Thioureaderivater som glutaminylcyclase-inhibitorer
JP2010533126A (ja) * 2007-07-13 2010-10-21 エーザイ・アール・アンド・ディー・マネジメント株式会社 神経因性疼痛の治療ためのampa受容体アンタゴニストとアセチルコリンエステラーゼ阻害剤との併用
US20090221554A1 (en) * 2008-02-28 2009-09-03 Zenyaku Kogyo Kabushiki Kaisha Method of treating cognitive impairment
FR2931677B1 (fr) * 2008-06-02 2010-08-20 Sanofi Aventis Association d'un agoniste partiel des recepteurs nicotiniques et d'un inhibiteur d'acetylcholinesterase, composition la contenant et son utilisation dans le traitement des troubles cognitifs
TW201010691A (en) * 2008-06-12 2010-03-16 Merz Pharma Gmbh & Co Kgaa 1-amino-alkylcyclohexane derivatives for the treatment of sleep disorders
JP2012501304A (ja) * 2008-09-10 2012-01-19 メルツ・ファルマ・ゲゼルシヤフト・ミト・ベシュレンクテル・ハフツング・ウント・コンパニー・コマンデイトゲゼルシヤフト・アウフ・アクティーン 耳鳴における認知障害を治療するための1−アミノ−アルキルシクロヘキサン誘導体
TWI478712B (zh) 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
CA2750028C (en) * 2009-01-20 2019-05-07 Guochuan Emil Tsai Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical
KR101755737B1 (ko) 2009-09-11 2017-07-07 프로비오드룩 아게 글루타미닐 사이클라제의 억제제로서 헤테로사이클릭 유도체
TWI491395B (zh) * 2009-09-30 2015-07-11 Ct Lab Inc 一種內含用以治療神經退化性疾病之立即釋出與長效釋出藥物的口服劑量配方
JP5885668B2 (ja) 2009-12-02 2016-03-15 アダマス ファーマシューティカルズ, インコーポレイテッド アマンタジン組成物および使用方法
CN109662964A (zh) * 2010-02-09 2019-04-23 约翰斯.霍普金斯大学 用于改善认知功能的方法和组合物
TR201001117A1 (tr) 2010-02-15 2011-09-21 Sanovel İlaç San.Ve Ti̇c.A.Ş. Dimebolin ve memantin kombinasyonları
ES2586231T3 (es) 2010-03-03 2016-10-13 Probiodrug Ag Inhibidores de glutaminil ciclasa
WO2011110613A1 (en) 2010-03-10 2011-09-15 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
PL2578212T3 (pl) * 2010-05-24 2017-01-31 Farmalider Sa Związek hamujący aktywację enzymu Erk 1/2 do zastosowania w leczeniu chorób neurodegeneracyjnych
AU2011328993B2 (en) 2010-11-15 2017-03-02 Agenebio, Inc. Pyridazine derivatives, compositions and methods for treating cognitive impairment
WO2012123563A1 (en) 2011-03-16 2012-09-20 Probiodrug Ag Benz imidazole derivatives as inhibitors of glutaminyl cyclase
WO2013160728A1 (en) 2012-04-26 2013-10-31 Alma Mater Studiorum - Universita' Di Bologna Dual targeting compounds for the treatment of alzheimer's disease
UA107653U (uk) 2012-10-01 2016-06-24 Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт" Композиція лікарських засобів для лікування та профілактики поведінкових, психічних та когнітивних розладів
EP3610890A1 (en) 2012-11-14 2020-02-19 The Johns Hopkins University Methods and compositions for treating schizophrenia
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
US11160785B2 (en) 2013-03-15 2021-11-02 Agenebio Inc. Methods and compositions for improving cognitive function
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
NZ760341A (en) 2013-12-20 2021-12-24 Agenebio Inc Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
MX383665B (es) * 2014-02-04 2025-03-14 Forest Laboratories Holdings Ltd Composiciones de donepezilo y métodos para tratar la enfermedad de alzheimer.
NZ738682A (en) 2015-05-22 2022-01-28 Agenebio Inc Extended release pharmaceutical compositions of levetiracetam
CA2990004C (en) 2015-06-19 2024-04-23 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
KR101882224B1 (ko) 2015-09-02 2018-07-26 한국프라임제약주식회사 콜린 알포세레이트 및 메만틴을 함유하는 복합 조성물
RU2737464C2 (ru) 2015-12-30 2020-11-30 Кориум Интернэшнл, Инк. Системы и способы длительного трансдермального введения
EP3405183A4 (en) 2016-01-18 2019-12-11 Arisan Therapeutics Inc. ADAMATE DERIVATIVES FOR TREATING A FILOVIRUS INFECTION
CN109563024B (zh) 2016-06-13 2023-06-06 心悦生医股份有限公司 苯甲酸锂的共晶及其用途
US11008277B2 (en) 2016-06-13 2021-05-18 Syneurx International (Taiwan) Corp. Co-crystals of sodium benzoate and uses thereof
JP7174632B2 (ja) 2016-06-23 2022-11-17 コリウム, インコーポレイテッド 親水性ドメインおよび疎水性ドメインならびに処置剤との接着剤マトリックス
JP7071958B2 (ja) 2016-07-27 2022-05-19 コリウム, インコーポレイテッド メマンチン経皮送達システム
CN109789133A (zh) 2016-07-27 2019-05-21 考里安国际公司 多奈哌齐透皮递送系统
KR102424270B1 (ko) 2016-07-27 2022-07-25 코리움, 인크. 경구 전달과 생물학적으로 동등한 약물동역학을 가진 경피 전달 시스템
US10336679B2 (en) 2016-10-24 2019-07-02 Syneurx International (Taiwan) Corp. Polymorphic forms of sodium benzoate and uses thereof
US11369579B2 (en) 2016-10-24 2022-06-28 Syneurx International (Taiwan) Corp. Polymorphic forms of sodium benzoate and uses thereof
BR112019012821A2 (pt) 2016-12-19 2019-11-26 Agenebio, Inc. derivados de benzodiazepina, composições e métodos para o tratamento do comprometimento cognitivo
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US11548893B2 (en) 2017-07-15 2023-01-10 Arisan Therapeutics Inc. Enantiomerically pure adamantane carboxamides for the treatment of filovirus infection
US20200166526A1 (en) * 2017-07-25 2020-05-28 William Beaumont Hospital Methods for diagnosing and treating alzheimer's disease
CN111372578A (zh) 2017-08-24 2020-07-03 阿达玛斯药物有限责任公司 金刚烷胺组合物、其制备和使用方法
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej
US10098861B1 (en) 2017-10-24 2018-10-16 Syneurx International (Taiwan) Corp. Pharmaceutical composition comprising sodium benzoate compound and clozapine, and uses thereof
AU2018392686A1 (en) 2017-12-20 2020-07-09 Corium Pharma Solutions, Inc. Transdermal adhesive composition comprising a volatile liquid therapeutic agent having low melting point
US10213393B1 (en) 2018-02-15 2019-02-26 Osmotica Kereskedelmi és Szolgáltató Korlátolt Feleõsségû Társaság Composition and method for treating neurological disease
US10213394B1 (en) 2018-02-15 2019-02-26 Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság Composition and method for treating neurological disease
US20190247331A1 (en) 2018-02-15 2019-08-15 Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság Composition and method for treating neurological disease
CA3104478A1 (en) 2018-06-19 2019-12-26 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
SI3843702T1 (sl) 2019-05-31 2023-12-29 Technimede, Sociedade Tecnico-Medicinal, SA Kombinacija memantina in donepezila v fiksnem odmerku s takojšnjim sproščanjem
FR3110393B1 (fr) * 2020-05-20 2022-05-06 Grn Consulting Compose et composition pour induire une neuroprotection
IL319072A (en) 2022-08-19 2025-04-01 Agenebio Inc History of Benzazepine, Compositions and Methods for Treating Cognitive Impairment
US12097189B1 (en) 2024-02-09 2024-09-24 Astellas Pharma Inc. Pharmaceutical composition for modified release

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7305644A (enExample) 1972-04-20 1973-10-23
DE2856393C2 (de) 1978-12-27 1983-04-28 Merz + Co GmbH & Co, 6000 Frankfurt Arzneimittel zur Behandlung von Morbus Parkinson
US5366738A (en) 1982-07-29 1994-11-22 Merck & Co., Inc. Controlled release drug dispersion delivery device
US4666829A (en) 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
US4663318A (en) * 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
US4816456A (en) * 1986-10-01 1989-03-28 Summers William K Administration of monoamine acridines in cholinergic neuronal deficit states
US5811128A (en) 1986-10-24 1998-09-22 Southern Research Institute Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor
NL195004C (nl) * 1987-03-04 2003-11-04 Novartis Ag Fenylcarbamaat bevattend farmaceutisch preparaat.
US4849222A (en) 1987-03-24 1989-07-18 The Procter & Gamble Company Mixtures for treating hypercholesterolemia
FI95572C (fi) * 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
JP2670680B2 (ja) 1988-02-24 1997-10-29 株式会社ビーエムジー 生理活性物質含有ポリ乳酸系微小球およびその製造法
US5506231A (en) 1989-03-31 1996-04-09 The Children's Medical Center Corporation Treatment of aids dementia, myelopathy and blindness
US5334618A (en) 1991-04-04 1994-08-02 The Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
DE58905637D1 (de) 1989-04-14 1993-10-21 Merz & Co Gmbh & Co Verwendung von Adamantan-Derivaten zur Prävention und Behandlung der cerebralen Ischämie.
US5912410A (en) 1990-06-15 1999-06-15 Scios Inc. Transgenic non-human mice displaying the amyloid-forming pathology of alzheimer's disease
US5614560A (en) 1991-04-04 1997-03-25 Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
US5288502A (en) 1991-10-16 1994-02-22 The University Of Texas System Preparation and uses of multi-phase microspheres
US5837672A (en) 1992-07-10 1998-11-17 Athena Neurosciences, Inc. Methods and compositions for the detection of soluble β-amyloid peptide
WO1995011010A1 (en) 1993-10-22 1995-04-27 Genentech, Inc. Methods and compositions for microencapsulation of antigens for use as vaccines
US6071966A (en) * 1997-06-30 2000-06-06 Merz + Co. Gmbh & Co. 1-amino-alkylcyclohexane NMDA receptor antagonists
DE69814878T2 (de) 1997-06-30 2004-05-19 Merz Pharma Gmbh & Co. Kgaa 1-amino-alkylcyclohexane als nmda-rezeptor-antagonisten
ATE313319T1 (de) * 1999-03-31 2006-01-15 Janssen Pharmaceutica Nv Vorgelatinierte stärke in einer formulierung mit gesteuerter freigabe
TW593223B (en) * 2000-06-20 2004-06-21 Merz Pharma Gmbh & Co Kgaa 1-amino-alkylcyclohexanes as 5-HT3 and neuronal nicotinic receptor antagonists
PL373903A1 (en) * 2002-05-31 2005-09-19 H.Lundbeck A/S A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease
EP1556019A2 (en) * 2002-10-24 2005-07-27 Merz Pharma GmbH & Co. KGaA Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
US20100130537A1 (en) * 2007-04-26 2010-05-27 Eisai R&D Management Co., Ltd Cinnamide compounds for dementia

Similar Documents

Publication Publication Date Title
JP2006506378A5 (enExample)
JP3984787B2 (ja) 機能性及び/又は器質性痛み症候群の治療のための製薬組成物の調製のためのアセチルコリンエステラーゼ阻害剤の使用
WO2005065069A3 (en) Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
JPS6143112A (ja) 精神性欲機能障害治療剤
JP2007508336A5 (enExample)
JP2016138142A (ja) 大うつ病を有する患者において減量療法を提供する方法
JPS59193821A (ja) 抗不安薬としてのフルオキセチンの使用法
JP2005508963A5 (enExample)
JPWO2008090736A1 (ja) アルツハイマー型認知症の予防及び治療のための医薬
RU2008119454A (ru) Лекарственное средство для защиты моторного нейрона у пациентов с боковым амиотрофическим склерозом
US10864191B2 (en) 5-HT6 receptor antagonists for use in the treatment of Alzheimer's disease with apathy as comorbidity
JP7123205B2 (ja) 経口用医薬組成物
JPH03170475A (ja) 抑うつ症治療剤
IE851848L (en) Propiophenone compound against sexual dysfunction
EP2830605B1 (en) A combination medicament comprising phenylephrine and paracetamol
US20190224208A1 (en) Pharmaceutical composition for treating premature ejaculation and method for treating premature ejaculation
HUP0200655A2 (hu) Osanetant alkalmazása kedélyállapot-rendellenességek kezelésére használható gyógyszerek előállítására
RU2002115814A (ru) Лечение системной красной волчанки с помощью дегидроэпиандростерона
JP2018502168A5 (enExample)
CN112437661A (zh) 苯甲酸或其盐用于预防或治疗抗n-甲基-d-天冬氨酸受体脑炎的用途
CN105311387B (zh) 复方手参丸在制备治疗原发性震颤药物中的应用
CN114080221B (zh) 用于减轻疼痛的布洛芬与曲马多的组合
JP2009501205A (ja) 精神病治療用組成物
JP2005527634A (ja) 緊張型頭痛の治療にミルナシプランを使用する方法
JP2022071083A (ja) うつ病を予防または治療するための安息香酸またはその塩および誘導体